VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriter’s Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million
18 déc. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Proposed Public Offering of Common Shares
12 déc. 2018 16h01 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
09 nov. 2018 07h00 HE
|
VBI Vaccines, Inc.
-- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively -- -- Encouraging early immunologic data observed in Phase 1/2a study of...
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
16 oct. 2018 08h00 HE
|
VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
VBI Vaccines Responds to Unfounded Allegations in Globes Article
16 sept. 2018 01h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Sept. 16, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”, the “Company”) is the subject of an article published in Globes, Israel business news, on September 12,...
VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
28 août 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development
15 août 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as...
VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference
06 août 2018 16h15 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit
09 juil. 2018 08h00 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Results of Annual General Meeting
25 mai 2018 16h15 HE
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., May 25, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious...